Before respiratory symptoms, many patients in China with COVID-19 had diarrhea, nausea, vomiting and abdominal discomfort, according to researchers. This was last week’s top story in gastroenterology.
Another top story highlighted recent findings that showed bile acid sequestrant IW-3718 reduced heartburn in patients with refractory GERD.
Read these stories and more below:
Patients with COVID-19 may experience GI symptoms, possible fecal-oral transmission
Results from two studies published in Gastroenterology discussed manifested gastrointestinal symptoms and possible fecal-oral transmission in patients with COVID-19, the disease caused by the novel coronavirus. Read more.
Bile acid sequestrant relieves refractory GERD symptoms
Recently published study results showed that the bile acid sequestrant IW-3718 reduced heartburn and regurgitation symptoms in patients with refractory GERD. Read more.
Before respiratory symptoms, many patients in China with COVID-19 had diarrhea, nausea, vomiting and abdominal discomfort, according to researchers.
Source: Adobe Stock
Shortened Stelara dose interval may improve activity in Crohn’s disease
Clinical and biological indices of disease activity improved in patients with Crohn’s disease when researchers shortened the Stelara 90 mg dose from every 8 weeks to every 4 weeks. Read more.
Physicians inappropriately favor discontinuing PPIs in high risk upper GI bleeding cases
Survey results revealed most internists perceived proton pump inhibitors were linked with numerous adverse events and recommended their discontinuation even in patients who are high risk for upper gastrointestinal bleeding. Read more.
Multitarget stool DNA has high positive predictive value in CRC
Non-invasive screening with multitarget stool DNA tests had a high positive predictive value for any colorectal neoplasia regardless of a patient’s exposure to previous colonoscopy, according to study results. Read more.